NuCana (NASDAQ:NCNA) Trading Down 1.5% – What’s Next?

NuCana PLC Sponsored ADR (NASDAQ:NCNA)’s stock price dropped 1.5% during mid-day trading on Thursday . The stock traded as low as $1.31 and last traded at $1.33. 31,744 shares were traded during trading, a decline of 49% from the average session volume of 62,270 shares. The stock had previously closed at $1.35.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of NuCana in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

NuCana Stock Down 1.5%

The firm has a market capitalization of $5.53 million, a P/E ratio of -0.45 and a beta of 2.23. The firm’s 50-day simple moving average is $1.80 and its 200-day simple moving average is $2.17.

NuCana (NASDAQ:NCNA) last released its quarterly earnings results on Friday, May 15th. The company reported ($1.25) EPS for the quarter, topping analysts’ consensus estimates of ($2.64) by $1.39.

Institutional Inflows and Outflows

An institutional investor recently raised its position in NuCana stock. FNY Investment Advisers LLC raised its position in shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,000 shares of the company’s stock after purchasing an additional 6,774 shares during the period. FNY Investment Advisers LLC owned approximately 33.33% of NuCana worth $36,000 at the end of the most recent reporting period. 44.00% of the stock is owned by institutional investors.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.